Liver monitoring on antipsychotics: when, why, what to do

Almost every antipsychotic is metabolised in the liver, and the liver is good at this job. Most people on long-term antipsychotic treatment never have a liver problem. A small but meaningful minority develop transient elevations in liver enzymes, and a much smaller number develop something more serious. Learning where the line is between "watch and recheck" and "stop and call your doctor" is one of the more useful pieces of self-knowledge in long-term care.

The basics: what the liver panel measures

• ALT (alanine aminotransferase) — released when liver cells are injured. Most specific to the liver.
• AST (aspartate aminotransferase) — also rises with liver injury but is found in muscle and other tissues too.
• ALP (alkaline phosphatase) — rises in bile duct problems and in bone disease.
• Bilirubin — the yellow pigment processed by the liver. High levels can cause jaundice.
• Albumin and INR — measure the liver's synthetic function (rarely affected by drug-induced liver injury unless severe).

The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) has clear plain-language guides.

Which antipsychotics affect the liver most?

Most antipsychotics produce small, transient ALT elevations in 10–30% of users, usually within the first 1–6 months and almost always asymptomatic. Significant injury is uncommon. Some agents have a slightly more notable profile:

• Chlorpromazine — can cause cholestatic hepatitis (rare but well-documented historically).
• Olanzapine and quetiapine — more likely to cause mild ALT elevations, often related to metabolic effects and fatty liver rather than direct toxicity.
• Clozapine — small risk of hepatitis, usually in the first month or two.
• Risperidone, paliperidone, aripiprazole, lurasidone — generally low hepatic risk.
• Valproate (used as augmentation) — well-known to cause hepatitis and hyperammonaemia in a small subset.
• Carbamazepine — can cause both transaminitis and rare severe hepatitis.

The LiverTox database from the NIH catalogues drug-induced liver injury for almost every prescription medication and is the best single reference if you want to look up your own.

Fatty liver: the quiet companion

Many antipsychotics increase weight, insulin resistance, and triglycerides — the same drivers of metabolic dysfunction-associated steatotic liver disease (MASLD), formerly called NAFLD. MASLD is now the most common cause of mildly elevated ALT in adults on metabolically active antipsychotics. It usually progresses slowly, but in a minority of patients can advance to fibrosis or cirrhosis. Lifestyle intervention (modest weight loss, reduced sugar and alcohol, increased activity) is the most effective treatment.

When are LFTs typically checked?

Practice varies, but a reasonable schedule is:

• Baseline when starting an antipsychotic or augmentation agent
• Repeat at 1–3 months for higher-risk medications (clozapine, valproate, chlorpromazine)
• Annually for routine monitoring on most antipsychotics
• Sooner for any new symptoms (see warning signs below)

How to interpret mildly abnormal LFTs

Most clinicians will consider:

• How high are the numbers? Mild elevations (less than 3 times the upper limit of normal) are usually watched and rechecked. Higher elevations prompt closer attention.
• Is bilirubin also elevated? Jaundice with elevated transaminases is more concerning than transaminitis alone (Hy's Law).
• Is the patient symptomatic?
• Are other contributors present (alcohol, hepatitis B/C, fatty liver, other medications)?

Often, the right next step is a recheck in 2–4 weeks plus screening for hepatitis B and C, an abdominal ultrasound, and a review of other contributors before changing antipsychotic.

Alcohol and antipsychotics

Alcohol stresses the liver directly and can amplify the metabolic effects of antipsychotics. There is no precise "safe" amount for someone on long-term antipsychotic treatment, but the general guidance from the CDC — no more than two standard drinks per day for men and one for women — is a reasonable upper limit, and less is better. People with elevated LFTs, fatty liver, or significant alcohol-related issues benefit most from cutting back substantially. See alcohol and schizophrenia.

Acetaminophen and other over-the-counter risks

Acetaminophen (paracetamol) is generally the safer option for pain in people with kidney issues but becomes the riskier option for the liver, especially when combined with alcohol or in doses above 3 grams a day. Stay below 3 g/day if you have any liver concerns and avoid the combination of alcohol and high-dose acetaminophen entirely.

Hepatitis B and C: worth knowing your status

Hepatitis B and C are more common in populations with severe mental illness for several reasons (rates of injection drug use, congregate living settings, gaps in healthcare access). Both are now treatable — hepatitis C is curable in most cases — and screening is recommended at least once for all adults. Ask your primary care doctor about a one-time hepatitis B and C screening if you've not had one.

What to bring up at your next visit

• When was your last liver panel?
• Are you on any medications (psychiatric or otherwise) that affect the liver?
• How much alcohol are you drinking honestly?
• Have you been screened for hepatitis B and C?
• If you have weight or metabolic issues, has anyone discussed fatty liver with you?

Most of these questions take five minutes. They occasionally save years.

This article is for educational purposes only and is not medical advice, diagnosis, or treatment. Always consult a qualified mental health professional. If you or someone you know is in crisis, call or text 988 in the US, or your local emergency number.